Back

Aldosterone synthase inhibition and the future CRM treatment landscape

19 May 2025 (13:03 - 13:13)
Organised by: Logo
Congress Presentation Part of: Does aldosterone synthase inhibition hold a key to transforming cardiorenal care? Aldosterone Antagonists HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

6 More presentations in this session

Presentation thumbnail
Welcome and introductions
Slides
Presentation thumbnail
The integrated nature of cardiorenal metabolic health
Professor L. Lund (Stockholm, SE)
Slides
Presentation thumbnail
The role of aldosterone and its part in cardiorenal disease
Doctor M. Costanzo (Naperville, US)
Slides
Presentation thumbnail
Insights from the vicadrostat phase 2 study and implications for further clinical development
Doctor R. Mentz (Durham, US)
Slides
Presentation thumbnail
Outlook, panel discussion and Q&A
Slides

Access the full session

Session thumbnail
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?
Video

The Event

Event poster

Heart Failure 2025

19 May 2025 13:03 CET
You may be interested in
thumbnail
Congress Presentation
Aldosterone synthase inhibition
2 September 2024
thumbnail
Webinar
MRAs in heart failure: what's old is new again
10 July 2023
thumbnail
Congress Presentation
A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
26 August 2022
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources